A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer
Status:
Unknown status
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This study will review the safety of picoplatin, a new type of platinum drug, with docetaxel,
a drug commonly used in the treatment of prostate cancer. Patients who are eligible for this
study will have had a diagnosis of hormone-refractory prostate cancer that has metastasized
to other areas of the body, and have not been previously treated with chemotherapy drugs.
Picoplatin will be administered in combination with docetaxel and prednisone to identify the
maximum tolerated dose (MTD). Patients will receive IV treatments of picoplatin with
docetaxel every 3 weeks, with prednisone, 5 mg orally, twice daily.